Dual Organic Modifier, Solid Core Technology and Quality by Design Based Tripartite Synergistic Model for Development and Validation of Stability Indicating Method by Reverse Phase-High Performance Liquid Chromatography for Assay and Impurities of Etoricoxib Tablets

被引:0
|
作者
Kolla, S. B. [2 ]
Vallabhaneni, M. R. [1 ]
Puttagunta, S. B. [3 ]
Chakka, V. V. S. M. [2 ]
机构
[1] Technol & Res Univ, Vignans Fdn Sci, Dept Chem, Guntur 522213, Andhra Pradesh, India
[2] GVK Biosci Private Ltd, Dept Analyt Res & Dev, Hyderabad 500076, Telangana, India
[3] Jawaharlal Nehru Technol Univ Kakinada, Vignan Coll Pharm, Dept Pharm, Guntur 522213, Andhra Pradesh, India
关键词
Design of experiments; solid core technology; dual organic modifier; assay and impurities method; impurity profile swap; etoricoxib; stability indicating; high performance liquid chromatography; SHELL PARTICLES; SELECTIVITY; SEPARATION; SOLVENT;
D O I
10.36468/pharmaceutical-sciences.964
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Tripartite synergistic model of solid core technology, dual organic modifiers and combined mixture design was implemented to achieve combined assay and related substances method by reverse phase-high performance liquid chromatography with short run time, enhanced sensitivity and improved resolution between multiple impurity peaks. pH of mobile phase, ternary mobile phase composition and high performance liquid chromatography column temperature are experimented as variable parameters. Acetonitrile and isopropyl alcohol mixture was experimented as dual organic modifier. Special focus was given to detailed methodology of dealing with elution order changes by assigning negative sign for resolution. Separation of etoricoxib and related impurities was evaluated as a case study to prove this concept. The method was developed with Ascentis (R) Express C-18, 150x4.6 mm, 2.7 mu column. Mobile phase comprised of buffer (0.1 % v/v ortho phosphoric acid, pH 3.6), acetonitrile and isopropyl alcohol (65.3:29:5.7 v/v) with a flow rate of 1.0 ml/min and ultraviolet detection at 285 nm. Forced degradation studies revealed that the method was stability indicating, suitable for both assay and impurities of drug product. The recoveries for impurities and assay were found to be in the range of 94.0 %-111.0 % and 97.9 %-101.8 %, respectively. Linearity was established for impurities and assay in the range of 0.25-2.0 mu g/ml and 125-750 mu g/ml, respectively. The method was validated as per international conference on harmonisation guidelines. The method can be successfully employed for determination of assay and impurities of etoricoxib in bulk drugs and formulations.
引用
收藏
页码:683 / 702
页数:20
相关论文
共 25 条
  • [11] Analytical Quality by Design Approach of Reverse-Phase High-Performance Liquid Chromatography of Atorvastatin: Method Development, Optimization, Validation, and the Stability-Indicated Method
    Alruwaili, Nabil K.
    INTERNATIONAL JOURNAL OF ANALYTICAL CHEMISTRY, 2021, 2021
  • [12] Quality by Design Approach Driven Development and Validation of Reverse Phase-High-Performance Liquid Chromatography Methodology for Dual Quantification of Aspirin and Rivaroxaban
    Patel, Mehul
    Patel, Hetali
    Patel, Rashmin
    Shah, Umang
    Thakkar, Mansi
    Patel, Ashish
    Patel, Swayamprakash
    Solanki, Nilay
    SEPARATION SCIENCE PLUS, 2024, 7 (12):
  • [13] Development and Validation of a Novel Stability-Indicating Reversed-Phase High-Performance Liquid Chromatography Method for Assay of Loratadine and Determination of Its Related Compounds
    Lu, Jun
    Wei, Yu-Chien
    Markovich, Robert J.
    Rustum, Abu M.
    JOURNAL OF AOAC INTERNATIONAL, 2010, 93 (03) : 891 - 903
  • [14] Stability-indicating method development for quantification of bromopride, its impurities, and degradation products by ultra-high performance liquid chromatography applying Analytical Quality by Design principles
    Abreu, Juliana Caldeira
    Mahr, Amanda Guiraldelli
    do Lago, Claudimir Lucio
    JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2021, 205
  • [15] Development and Validation of a Stability-Indicating Assay Method for Simultaneous Determination of Perindopril and Indapamide in Combined Dosage Form by Reversed-Phase High-Performance Liquid Chromatography
    Jogia, Hitesh
    Khandelwal, Umesh
    Gandhi, Tripti
    Singh, Sukhdev
    Modi, Darshana
    JOURNAL OF AOAC INTERNATIONAL, 2010, 93 (01) : 108 - 115
  • [16] Development and validation of a novel stability-indicating reversed-phase high-performance liquid chromatography method for assay of milbemycin oxime and estimation of its related compounds
    Huang, Junmin
    Rustum, Abu
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2015, 250
  • [17] Reversed-phase high-performance liquid chromatography analytical method development and validation for cefepime and sulbactam injection formulation assay: A quality by design approach
    Mondal, Sitanshu
    Asati, Vivek
    Verma, Sant Kumar
    Gupta, Ghanshyam Das
    Kurmi, Balak Das
    Patel, Preeti
    SEPARATION SCIENCE PLUS, 2023, 6 (04)
  • [18] Development and Validation of a Stability-Indicating Reversed-Phase High-Performance Liquid Chromatography Method for Assay of Doramectin and Estimation of its Related Substances in Commercial Batches of Doramectin Drug Substance
    Wang, Lin
    Wimalasinghe, Rasangi
    Padivitage, Nilusha
    Rustum, Abu M.
    JOURNAL OF AOAC INTERNATIONAL, 2021, 104 (05) : 1238 - 1245
  • [19] Development and Validation of a Stability-Indicating Reversed-Phase High-Performance Liquid Chromatography (RP-HPLC) Method for Identification, Assay, and Estimation of Related Substances of Ivermectin Drug Substance
    Wimalasinghe, Rasangi M.
    Zhao, Daoli
    Wang, Lin
    Rustum, Abu
    JOURNAL OF AOAC INTERNATIONAL, 2021, 104 (06) : 1505 - 1513
  • [20] Development and validation of a stability-indicating high performance liquid chromatography method based on a core-shell octadecyl column to determine Avermectin and its related substances in bulk Avermectin batches
    Berger, Shane N.
    Rustum, Abu M.
    JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2025, 259